The cost-effectiveness of saxagliptin versus NPH insulin when used in combination with other oral antidiabetes agents in the treatment of type 2 diabetes mellitus in Poland

Diabetes Technology and Therapeutics

Volumn 14, Issue 1, 2012, Pages 65-73

  Grzeszczak, Wladyslaw ^a   Czupryniak, Leszek ^b   Kolasa, Katarzyna ^c,d   Sciborski, Cezary ^c,d   Lomon, Isabelle Duprat ^c   McEwan, Phil ^e  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

^b N Barlicki University Hospital No 1 of Medical University of Lodz   (Poland)

^c BRISTOL MYERS SQUIBB   (United States)

^d MEDICAL UNIVERSITY OF WARSAW   (Poland)

^e Cardiff Research Consortium   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLICLAZIDE; HEMOGLOBIN A1C; ISOPHANE INSULIN; METFORMIN; SAXAGLIPTIN; SULFONYLUREA;

ADULT; AMPUTATION; ARTICLE; BLINDNESS; COMBINATION CHEMOTHERAPY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DIABETIC ANGIOPATHY; DIABETIC MICROANGIOPATHY; DISEASE COURSE; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; FEMALE; HEART INFARCTION; HUMAN; HYPOGLYCEMIA; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; POLAND; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; STROKE; WEIGHT GAIN;

ADAMANTANE; COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; DIPEPTIDES; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN, ISOPHANE; MALE; METFORMIN; MIDDLE AGED; MODELS, ECONOMIC; POLAND; QUALITY-ADJUSTED LIFE YEARS; SULFONYLUREA COMPOUNDS;

EID: 84855446813     PISSN: 15209156     EISSN: 15578593     Source Type: Journal    
DOI: 10.1089/dia.2011.0092     Document Type: Article

References (33)

1. Diabetes-The Policy Puzzle: Towards Benchmarking in the EU 25. www.fend.org/news-assets/DiabetesReport.pdf (accessed June 2010).
2. Kinalska I, Niewada M, Glogowski C, Krzyzanowska A, Gierczynaski J, qatek M, Kamináski B: Koszty cukrzycy typu 2w Polsce (badanie CODIP). Diabetologia Praktyczna 2004;5:1-8.
3. Zalecenia kliniczne dotycza?ce poste?powania u chorych na cukrzyce?. Stanowisko Polskiego Towarzystwa Diabetologicznego. Diabetologia Praktyczna 2010;11(Suppl A):A1-A47.
4. Asche CV, McAdam-Marx C, Shane-McWhorter L, Sheng X, Plauschinat CA: Association between oral antidiabetic use, adverse events and outcomes in patients with type 2 diabetes. Diabetes Obes Metab 2008;10:638-645. (Pubitemid 352044293)
5. Rubino A, McQuay LJ, Gough SC, Kvasz M, Tennis P: Delayed initiation of subcutaneous insulin therapy after failure of oral glucose-lowering agents in patients with type 2 diabetes: a population-based analysis in the UK. Diabet Med 2007;24:1412-1418. (Pubitemid 350179434)
6. Peyrot M, Rubin RR, Lauritzen T, Skovlund SE, Snoek FJ, Matthews DR, Landgraf R, Kleinebreil L: Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care 2005;28:2673-2679. (Pubitemid 43951158)
7. McEwan P, Peters JR, Bergenheim K, Currie CJ: Evaluation of the costs and outcomes from changes in risk factors in type 2 diabetes using the Cardiff stochastic simulation costutility model (DiabForecaster). Curr Med Res Opin 2006; 22:121-129. (Pubitemid 43106915)
8. The Mount Hood 4 Modeling Group: Computer modeling of diabetes and its complications: a report on the fourth Mount Hood challenge meeting. Diabetes Care 2007;30:1638-1646.
9. Kolasa K, Niewada M, Puelles Fernandez de Troconiz J, Townsend R, McEwan P: The cost-effectiveness of saxagliptin versus NPH insulin in the treatment of type 2 diabetes mellitus (T2DM) in Poland [abstract]. Value Health 2010;13:A290.
10. Clarke PM, Gray AM, Briggs A, Farmer AJ, Fenn P, Stevens RJ, Matthews DR, Stratton IM, Holman RR; UK Prospective Diabetes Study (UKPDS) Group: A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). Diabetologia 2004;47: 1747-1759. (Pubitemid 40022410)
11. Jadzinsky M, Pfuätzner A, Paz-Pacheco E, Xu Z, Allen E, Chen R; CV 181-039 Investigators: Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes Obes Metab 2009;11:611-622.
12. Nauck MA, Meininger G, Sheng D, Terranella L, Stein PP: Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2007;9:194-205. (Pubitemid 46206563)
13. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:837-853.
14. Rosenstock J, Aguilar-Salinas C, Klein E, Nepal S, List J, Chen R; CV181-011 Study Investigators: Effect of saxagliptin monotherapy in treatment-naive patients with type 2 diabetes. Curr Med Res Opin 2009;25:2401-2411.
15. Scott R, Loeys T, Davies MJ, Engel SS; Sitagliptin Study 801 Group: Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes. Diabetes Obes Metab 2008;10:959-969.
16. Saenz A, Fernandez-Esteban I, Mataix A, Segura MA, Roqueái Figuls M, Moher D: Metformin monotherapy for type 2 diabetes mellitus. Cochrane Database Syst Rev 2005;(3): CD002966.
17. Monami M, Marchionni N, Mannucci E: Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: a meta-analysis. Diabetes Res Clin Pract 2008;81:184-189.
18. DeFronzo RA, Hissa MN, Garber AJ, Luiz Gross J, Yuyan Duan R, Ravichandran S, Chen RS; Saxagliptin 014 Study Group: The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care 2009; 32:1649-1655.
19. Chacra AR, Tan GH, Apanovitch A, Ravichandran S, List J, Chen R; CV181-040 Investigators: Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial. Int J Clin Pract 2009;63:1395-1406.
20. Pradhan AD, Everett BM, Cook NR, Rifai N, Ridker PM: Effects of initiating insulin and metformin on glycemic control and inflammatory biomarkers among patients with type 2 diabetes: the LANCET randomized trial. JAMA 2009; 302:1186-1194.
21. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill MC, Zinman B, Viberti G; ADOPT Study Group: Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427-2443. (Pubitemid 44903747)
22. Krol ZJ: Guidelines for Conducting Health Technology Assessment (HTA) Poland. Warsaw: Warsaw Agency for Health Technology Assessment, 2009.
23. United Kingdom Department of Health. Health Survey for England. 2003. www.dh.gov.uk/en/PublicationsAndStatistics/PublishedSurvey/ HealthSurveyForEngland/HealthSurvey Results/DH-4098913 (accessed August 10, 2010).
24. Clarke P, Gray A, Holman R: Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decis Making 2002;22:340-349. (Pubitemid 34791321)
25. Lee AJ, Morgan CL, Conway P, Currie CJ: Characterisation and comparison of health-related quality of life for patients with renal failure. Curr Med Res Opin 2005;21:1777-1783. (Pubitemid 41667245)
26. Caro JJ, Stillman IP, Danel A, Getsios D, McEwan P: Cost effectiveness of rimonabant use in patients at increased cardiometabolic risk: estimates from a Markov model. J Med Econ 2007;10:239-254. (Pubitemid 47478747)
27. Currie CJ, Morgan CL, Poole CD, Sharplin P, Lammert M, McEwan P: Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes. Curr Med Res Opin 2006;22:1523-1534. (Pubitemid 44297431)
28. Chancellor J, Aballeaa S, Lawrence A, Sheldon R, Cure S, Plun-Favreau J, Marchant N: Preferences of patients with diabetes mellitus for inhaled versus injectable insulin regimens. Pharmacoeconomics 2008;26:217-234. (Pubitemid 351271380)
29. Peyrot M, Rubin RR, Khunti K: Addressing barriers to initiation of insulin in patients with type 2 diabetes. Prim Care Diabetes 2010;4(Suppl 1):S11-S18.
30. Jarosz M, Rychlik E: Overweight and obesity among adults in Poland, 1983-2005. Adv Med Sci 2008;53:158-166.
31. Polonsky WH: Emotional and quality-of-life aspects of diabetes management. Curr Diabetes Rep 2002;2:153-159.
32. Hollander PA, Kushner P: Type 2 diabetes comorbodities and treatment challenges: rationale for DPP-4 inhibitors. Postgrad Med 2010;122:71-80.
33. Emslie-Smith AM, Boyle DI, Evans JM, Sullivan F, Morris AD: Contraindications to metformin therapy in patients with Type 2 diabetes-a population-based study of adherence to prescribing guidelines. Diabet Med 2001;18: 483-488. (Pubitemid 32738698)